Not Yet Recruiting
A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07703657
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Clinically Significant EBV DNAemia, Epstein-Barr Virus Reactivation
- Locations
-
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Tianjin, China